D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. 1994

J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
State Mental Hospital Haar, Germany.

To investigate whether the occurrence of extrapyramidal side effects was related to D2 dopamine receptor occupancy, iodobenzamide single positron emission computed tomography was carried out in 27 schizophrenic patients and 10 controls. Eighteen patients were treated with haloperidol; 9 patients were treated with clozapine. Our data suggest a relationship between D2 receptor occupancy and extrapyramidal side effects as well as the existence of a neuroleptic threshold of a striatal:frontal cortex ratio of 1.2, below which drug-induced exptrapyramidal side effects can be expected.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005116 Extrapyramidal Tracts Uncrossed tracts of motor nerves from the brain to the anterior horns of the spinal cord, involved in reflexes, locomotion, complex movements, and postural control. Extrapyramidal Tract,Tract, Extrapyramidal
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
February 2004, Journal of clinical psychopharmacology,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
September 1998, Pharmacopsychiatry,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
September 1997, Psychiatry research,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
April 2001, Progress in neuro-psychopharmacology & biological psychiatry,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
August 2023, Molecular psychiatry,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
July 1992, Archives of general psychiatry,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
August 2005, International journal of clinical pharmacology and therapeutics,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
October 2002, Synapse (New York, N.Y.),
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
January 1999, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
J Scherer, and K Tatsch, and J Schwarz, and W H Oertel, and M Konjarczyk, and M Albus
February 1997, International clinical psychopharmacology,
Copied contents to your clipboard!